https://www.selleckchem.com/pr....oducts/pf-3758309.ht
In the CoreValve High-Risk Trial, patients with severe symptomatic aortic stenosis had similar clinical outcomes with transcatheter aortic valve replacement (TAVR) vs surgical aortic valve replacement (SAVR) over 5 years of follow-up, with mortality rates of more than 50% in both groups. To describe the long-term health status of surviving patients randomized to self-expanding TAVR vs SAVR. This randomized clinical trial included patients at high surgical risk with severe aortic stenosis who completed a baseline Kansas City Cardiomyo
Like
Comment
Share
